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Research article A systematic review and meta-analysis of bone 
metabolism in prostate adenocarcinoma
Ary Serpa Neto1, Marcos Tobias-Machado1,2, Marcos AP Esteves1,2, Marília D Senra2,3, Marcelo L Wroclawski1,2, 
Fernando LA Fonseca2,3, Rodolfo B dos Reis4, Antônio CL Pompeo1 and Auro Del Giglio*2,3
Background: Osteoporosis could be associated with the hormone therapy for metastatic prostate carcinoma (PCa) 
and with PCa per se. The objective of this review is to determine the incidence of bone loss and osteoporosis in patients 
with PCa who are or are not treated with hormone therapy (ADT).
Methods: The Medline, Embase, Cancerlit, and American Society of Clinical Oncology Abstract databases were 
searched for published studies on prostate cancer and bone metabolism. The outcomes assessed were: fracture, 
osteoporosis and osteopenia.
Results: Thirty-two articles (116,911 participants) were included in the meta-analysis. PCa patients under ADT had a 
higher risk of osteoporosis (RR, 1.30; p < 0.00001) and a higher risk of fractures (RR, 1.17; p < 0.00001) as compared to 
patients not under ADT. The total bone mineral density was lower in patients under ADT when compared with patients 
not under ADT (p = 0.031) but it was similar to bone mineral density found in healthy controls (p = 0.895). The time of 
androgen deprivation therapy correlated negatively with lumbar spine and total hip bone mineral density (Spearman's 
rho = -0.490 and -0.773; p = 0.028 and 0.001, respectively) and with total hip t score (Spearman's rho = -0.900; p = 0.037).
Conclusion: We found consistent evidence that the use of androgen deprivation therapy in patients with PCa reduces 
bone mineral density, increasing the risk of fractures in these patients.
Background
Prostate cancer (PCa) is the most common cancer in men
in many Western countries and is the second leading
cause of cancer death in men [1]. PCa is characterized by
its propensity for bone metastases which occur in more
than 80% of patients with advanced prostate cancer [2,3].
Typical metastasis sites include the spine, pelvis and rib
cage[4]. The median survival time of patients with PCa is
approximately three years after the development of bone
metastases, and during this period, patients are at risk of
pain, hypercalcaemia, fracture and spinal cord compres-
sion [5].
Another feature of patients with PCa is bone loss and,
in a more advanced period, osteoporosis. Antihormonal
therapy used to inhibit the disease progression or prevent
its recurrence can lead to changes in bone metabolism,
resulting in the loss of bone mineral density (BMD) since
this therapy depletes circulating levels of oestrogens and
androgens that maintain bone mass through the suppres-
sion of bone reabsorption and promotion of bone forma-
tion [6]. These pathological changes are known as cancer
treatment-induced bone loss (CTIBL). However, patients
with prostate cancer typically have low bone mineral den-
sity (BMD) even before receiving hormone therapy as a
result of age, underlying disease, or other co-morbidities
[7].
Bone mass loss and osteoporosis may cause an
increased risk of fractures due to a reduction in bone vol-
ume and microarchitectural deterioration. The WHO
expert committee defines osteoporosis as a hip bone min-
eral density level (dual x-ray absorptiometry) of more
than 2.5 SD below the mean for young, white, adult men
(with a t-score of at least - 2.5 SD) in men age 65 years
and older and in men from 50 to 64 years of age if other
risk factors for fracture are presented [8]. The most sig-
nificant complications of osteoporosis are fractures of the
hip, forearm, and vertebrae. The occurrence of fractures
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significantly correlate with shorter survival in men with
prostate cancer. When fracture history was evaluated, the
median overall survival time was 39 months longer in
men without a history of skeletal fracture. Therefore, a
better understanding of the magnitude and prevalence of
bone loss in these patients is critical [9,10].
The objective of this review is to determine the inci-
dence of bone loss and osteoporosis in patients with PCa
who are or are not treated with hormone therapy.
Methods
Search methods for identification of studies
Studies were identified through a computerized search of
Medline (1966-2009), Cancerlit (1966-2009), and Embase
(1990-2009), databases using the following as search
query: "prostate cancer and (osteoporosis or bone min-
eral density)". A computerized search of the Proceedings
of the Annual Meetings of the American Society of Clini-
cal Oncology (ASCO) held between 1998 and 2008 was
also performed to identify relevant studies published in
abstract form. Lastly, all review articles and all cross-ref-
erenced studies from retrieved articles were screened for
pertinent information.
Selection of studies
The meta-analysis was limited to studies that involved
with the relationship of prostate cancer and/or hormone
therapy with osteoporosis and in any language. For the
incidence analysis all studies that report these rates were
included (Table 1). Studies were excluded if fracture out-
come or BMD data were not provided, or if they included
patients with other bone or mineral disorders. When we
found duplicate reports of the same study in preliminary
abstracts and articles, we analyzed the data from the most
complete data set.
Data extraction and statistical management
Data were independently extracted from each report by
M.A.P.E, A.S.N and M.D.S, using a data recording form
developed for this purpose. After extraction, data were
reviewed and compared by A.S.N. Instances of disagree-
ment between the two other data extractors were
resolved by consensus among the investigators. When-
ever needed, we obtained additional informations about a
specific study by directly questioning the principal inves-
tigator.
For the fracture analysis, we computed a pooled esti-
mate of the risk ratios (RRs) of each study using a fixed
effect model according to Mantel and Haenszel and
graphically represented these results in forest plot graphs.
The homogeneity assumption was verified with a χ2 test,
using a df equal to the number of analyzed studies minus
o ne . An est im a t e  of  t he  pot e n t ial  p ubli ca ti on bias was
performed by plotting the single study RR on a log-scale
against the respective standard error (SE) creating a fun-
nel plot. We used bivariate correlations with the Spear-
man's rho coefficient to assess the relationship between
ADT time and bone mineral density.
For all analyses, p values < 0.05 were considered signifi-
cant. For publication bias, p values < 0.1 were considered
significant.
Results
Literature search
The search strategy retrieved 361 unique citations: 314
from MEDLINE and 47 from EMBASE. Of these, 287
were excluded after the first screening, which was based
on abstracts or titles, leaving 74 articles for full-text
review (Figure 1). During this review, 42 articles were
excluded for the following reasons: they involved ran-
domized controlled trials with bisphosphonate therapy (n
= 33); the same cohort was previously analyzed (n = 2); or
the bone mineral density, t or z-scores or osteoporosis/
osteopenia rate was not shown (n = 7). Finally, 32 articles
(116,911 participants) were included in the meta-analy-
sis.
Study characteristics
The characteristics of the 32 selected studies are shown
in Table 1[11-41]. With two exceptions [14,41], all studies
reported bone mineral density values as assessed by dual
energy X-ray absorptiometry. Eleven studies reported
biomarkers of bone turnover biomarkers, including alka-
line phosphatase and cross-linked N-telopeptide of type I
collagen (NTx). Twelve studies evaluated patients with
prostate cancer (PCa) under androgen deprivation ther-
apy (ADT); eight evaluated the same cohort of patients
with PCa before and after the ADT; five evaluated
patients with PCa, patients with PCa under ADT and
healthy controls; three evaluated patients with PCa and
patients with PCa under ADT; two evaluated patients
with PCa under ADT and healthy controls; and two eval-
uated only patients with PCa.
The selected studies were published between 1997 and
2009, and the number of participants per study ranged
from 12 to 50,613, for a total of 116,911 participants. At
the baseline, the number of participants with PCa was
70,684, the number of participants with PCa under ADT
was 45,161, and the number of healthy controls was
1,066. The mean age of the participants varied from 66 to
79 years (72.33 ± 3.12 years), and the mean time of ADT
in the patients treated with this therapy varied from 2.9 to
120 months (36.98 ± 31.29 months). The risk ratios for
osteoporosis, osteopenia and fractures were determined
for seven, two and five studies respectively.
General characteristics of the patients
The general characteristics of the participants are
described in Table 2. Patient age was similar in all groups.
The total bone mineral density was lower in patientsSerpa Neto et al. BMC Urology 2010, 10:9
http://www.biomedcentral.com/1471-2490/10/9
Page 3 of 10
Table 1: Characteristics of studies included in the meta-analysis
Bone Metabolism Assessment
Source Total No. Of Patients DEXA Biomarkers of 
Turnover
Type of Patients
Agarwall et al,[11]
2004
50 Yes None PCa before and after ADT
Ahlborg et al,[12]
2008
754 Yes None PCa, PCa with ADT and controls
Bernat et al,[13]
2005
18 Yes None PCa with ADT
Berruti et al,[14]
2005
200 None Yes PCa with ADT
Bruder et al,[15]
2006
89 Yes Yes PCa with ADT
Chen et al,[16]
2001
109 Yes None PCa with ADT and controls
Conde et al,[17]
2004
34 Yes None PCa
Daniell et al,[18]
2000
54 Yes None PCa, PCa with ADT and controls
Diamond et al,[19]
2004
87 Yes Yes PCa with ADT
Galvão et al,[20]
2008
72 Yes Yes PCa before and after ADT
Greenspan et al,[21]
2005
195 Yes Yes PCa, PCa with ADT and controls
Hatano et al,[22]
2000
218 Yes Yes PCa with ADT
Higano et al,[23]
2004
17 Yes None PCa before and after ADT
Kiratli et al,[24]
2001
36 Yes None PCa, PCa with ADT and controls
Lee et al,[25]
2005
65 Yes None PCa before and after ADT
Maillefert et al,[26]
1999
12 Yes Yes PCa before and after ADT
Malcolm et al,[27]
2007
395 Yes None PCa with ADT
Miyaji et al,[28]
2004
27 Yes Yes PCa before and after ADT
Morote et al,[29]
2007
390 Yes None PCa before and after ADT
Oefelein et al,[9]
2002
195 Yes None PCa with ADT
Panju et al,[30]
2008
66 Yes None PCa with ADT
Ryan et al,[31]
2007
120 Yes None PCa with ADT
Shahinian et al,[32]
2005
50,613 Yes None PCa and PCa with ADT
Smith et al,[33]
2001
41 Yes Yes PCaSerpa Neto et al. BMC Urology 2010, 10:9
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under ADT when compared with patients without ADT
(p = 0.031), but it was similar to those found in healthy
controls (p = 0.895). The total bone mineral density of the
total hip was lower in patients under ADT when com-
pared with patients without ADT (p = 0.002), but it was
similar to those values found in healthy controls (p  =
0.211). The z score was similar in all groups, and the t
score of the lumbar spine and total hip was lower in
patients under ADT when compared with patients with
PCa without ADT (p = 0.031 and p = 0.021, respectively).
The time of androgen deprivation therapy correlated neg-
atively with lumbar spine and total hip BMD (Spearman's
rho = -0.490 and -0.773; p = 0.028 and 0.001, respectively)
and with total hip t score (Spearman's rho = -0.900; p =
0.037). (Figure 2)
The incidence of osteoporosis was higher in patients
under ADT when compared with patients with PCa with-
out ADT (p < 0.001), but it was lower when compared
with the healthy controls (p < 0.001). However, patients
under ADT had a higher number of fractures when com-
pared with patients with PCa and healthy controls (p <
0.001 for both comparisons).
Risk of osteoporosis and fracture
Among the five selected studies that analyzed patients
under ADT and patients with PCa only, all found an asso-
ciation between androgen deprivation therapy and an
increased risk of osteoporosis. Patients with PCa under
androgen deprivation therapy had an increased risk of
developing osteoporosis as compared to patients with
PCa who were not under ADT, with a pooled risk ratio
(RR) of 1.30 (95% CI, 1.22 - 1.40) (Figure 3A).
Of the two studies that analyzed patients with PCa not
under ADT and healthy controls, neither found an asso-
ciation between PCa and an increased risk of osteoporo-
sis. Patients with PCa without ADT had a reduced risk of
developing osteoporosis as compared to healthy controls,
with a pooled RR of 0.39 (95% CI, 0.16 - 0.96) (Figure 3B).
Patients under ADT had a higher risk of developing
osteoporosis when compared to healthy controls (RR,
2.26; 95% CI, 1.00 - 5.09).
Among the five selected studies that analyzed patients
with PCa under ADT and patients with PCa without
ADT, all found an association between androgen depriva-
tion therapy and an increased risk of fractures, with a
pooled RR of 1.17 (95% CI, 1.14 - 1.20), but with signifi-
cant heterogeneity of RRs across studies (p < 0.0001; I2,
Smith et al,[34]
2005
11,661 Yes None PCa and PCa with ADT
Smith et al,[35]
2006
12,120 Yes None PCa and PCa with ADT
Spanjol et al,[36]
2008
398 Yes None PCa with ADT
Stoch et al,[37]
2001
257 Yes Yes PCa, PCa with ADT and controls
Townsend et al,[38]
1997
224 Yes None PCa with ADT
Wei et al,[39]
1999
32 Yes None PCa before and after ADT
Yamada et al,[40]
2007
204 Yes Yes PCa with ADT and controls
Alibhai et al,[41]
2009
38,158 None None PCa with ADT and controls
DEXA: Dual energy X-ray absorptiometry; PCa: Prostate cancer; ADT: Androgen deprivation therapy
Table 1: Characteristics of studies included in the meta-analysis (Continued)
Figure 1 Flowchart of the meta-analysis.Serpa Neto et al. BMC Urology 2010, 10:9
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96%). These measurements of heterogeneity were likely a
result of the extremely large overall number of partici-
pants in our analysis (111,573 participants). The point
estimates of the RRs were consistently greater than one in
all studies. (Figure 4)
To explore the study heterogeneity, we performed strat-
ified analyses across a number of key study characteris-
tics and clinical factors (Table 3). The finding that
patients under ADT had an increased fracture risk was
consistently found in all of the stratified analyses. For
example, when stratified by the type of the fracture,
patients under ADT seemed to have a higher risk of lum-
bar spine fracture than of hip/femur fracture.
Publication bias
The visual inspection of the Begg funnel plot that is
related to figure 3A did not revealed asymmetry (p  =
0.219) (Figure 5A). This finding is consistent with a small
possibility of publication bias, as confirmed by the Begg
test (z = 1.47; p = 0.142). The visual inspection of the
Begg funnel plot that is related to figure 3B did not
revealed asymmetry (p = 0.193) (Figure 5B). This results
excludes the possibility of publication bias, as confirmed
by the Begg test (z = 0.68; p = 0.497).
Discussion
An extensive body of literature reports on the association
between androgen deprivation therapy and the incidence
of osteoporosis. All the five studies that we identified, and
that met the inclusion criteria, indicated a positive associ-
ation between ADT and osteoporosis. In relation to frac-
tures, all four of the identified studies indicated a positive
association between ADT and the incidence of fractures.
Furthermore, the association persisted and remained sta-
tistically significant across a number of stratified analyses
that explored clinical and study quality factors.
Observational primary studies usually cannot prove
causality. However, the studies in this review presented
an appropriate temporal relationship; the androgen
deprivation therapy and the diagnosis of prostate cancer
diagnosis preceded the incidence of osteoporosis and
fractures in all of the studies. Furthermore, androgen
deprivation therapy depletes the circulating levels of
oestrogens and androgens that maintain bone mass
Table 2: General characteristics of the participants
PCa and ADT (n = 26,082) p* PCa w/ADT (n = 51,605) p** Controls (n = 1,066) p***
Age (years) 72.3 ± 3.12 > 0.05 70.2 ± 2.81 > 0.05 70.3 ± 3.30 > 0.05
ADT time (months) 36.9 ± 31.2 --- --- --- --- ---
Total BMD (g/cm2) 0.90 ± 0.34 0.031 1.07 ± 0.11 0.760 0.96 ± 0.20 0.895
LS BMD (g/cm2) 1.02 ± 0.10 0.083 1.10 ± 0.13 0.806 1.05 ± 0.18 0.868
TH BMD (g/cm2) 0.89 ± 0.08 0.002 1.010.08 0.823 0.97 ± 0.03 0.211
t score (Total) -1.30 ± 1.10 0.282 -0.26 ± 1.14 --- --- ---
t score (LS) -0.27 ± 1.21 0.031 0.25 ± 0.07 --- --- ---
t score (TH) -0.94 ± 0.24 0.021 -0.55 ± 0.07 --- --- ---
z score (Total) -0.30 ± 0.69 0.164 0.54 ± 0.15 --- --- ---
z score (LS) -0.27 ± 1.31 --- --- --- --- ---
z score (TH) -0.33 ± 0,65 0.555 0.05 ± 0.35 --- --- ---
Osteoporosis (%) 5.30 < 0.001 2.89 < 0.001 10.3 < 0.001
Osteopenia (%) 1.01 < 0.001 0.15 < 0.001 1.4 0.278
Fracture (%) 17.56 < 0.001 15.62 < 0.001 1.5 < 0.001
Vertebral fracture 
(%)
2.96 < 0.001 1.90 --- --- ---
Superior member 
fracture (%)
4.45 < 0.001 2.47 --- --- ---
Inferior member 
fracture (%)
9.77 < 0.001 7.38 --- --- ---
LS: Lumbar spine; TH: Total hip
*: PCa and ADT vs PCa w/ADT
**: PCa w/ADT vs Controls
***: Controls vs PCa and ADTSerpa Neto et al. BMC Urology 2010, 10:9
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through suppression of bone reabsorption and promo-
tion of bone formation [6]. These facts impart biological
plausibility to our findings on the association between
PCa and ADT with osteoporosis and fractures as shown
by the forests plots (Figure 3A, 3B and 4).
The lack of adjustment for the presence of metastasis
(only one study adjusted for this factor), calcium inges-
tion (no studies) and genetic predisposition (no studies)
must be considered as a limitation of our study. The pres-
ence of metastasis, a low calcium ingestion and patients
with history of osteoporosis in the family had a higher
risk of osteopenia, osteoporosis and fractures.
It is estimated that two million men are affected by
osteoporosis in the United States. Although men experi-
Figure 2 Scatter plot of lumbar spine (black circles) and total hip (white circles) BMD and ADT time.
Figure 3 Adjusted risk ratios. A, Adjusted risk ratio of osteoporosis for patients under ADT as compared to patients not under ADT. B, Adjusted risk 
ratio of osteoporosis for patients with PCa as compared to healthy controls.Serpa Neto et al. BMC Urology 2010, 10:9
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ence a gradual age-related loss of BMD of 7 to 12% per
decade beginning at age 30, primary male osteoporosis is
not common [42]. Most men who have clinically signifi-
cant osteoporosis are older than 70 years of age and have
risk factors that contribute to decreased bone mineraliza-
tion, such as hypogonadism, thyroid and parathyroid dis-
orders, glucocorticoid excess, alcoholism, osteomalacia,
and malignancy [43]. The relationship between decreased
BMD and ADT is well established. Androgen suppression
reduces BMD approximately 3% to 7% per year [44].
Recent reports have demonstrated that men who have
prostate cancer and are receiving ADT have BMD mea-
surements from 6.5% to 17.3% lower than men who are
not treated with ADT [7]. One study reported that spinal
and femoral BMD values were 1.7% and 5.2% less after
two years and 14% and 28% less after 10 years of ADT,
respectively, as compared to age-matched control sub-
jects [24].
Although some studies defend the idea that PCa
patients (without ADT) have lower levels of BMD and
higher rates of osteoporosis, we were not able to verify
this finding in our study. In fact, patients with prostate
cancer showed similar levels of BMD and lower rates of
osteoporosis when compared with healthy controls.
Assessed individually, three studies showed similar levels
of BMD between PCa patients and healthy controls
[21,24,37], one showed higher levels for the PCa group
[12] and one showed lower levels [18]. With respect to
osteoporosis, all studies showed lower rates in the PCa
group as compared to healthy controls [12,21]. One
potential explanation for these findings is the highly
debated association of a high endogenous androgen levels
with the risk of prostate cancer, which may potentially
explain the higher BMD seen in patients with PCa before
they receive ADT as compared to normal men [45]. We
w e r e  u n a b l e  t o  e v a l u a t e  t h i s  h y p o t h e s i s  i n  o u r  s t u d y
because only two of the evaluated studies had data on tes-
tosterone levels. Nevertheless, the prevalence of osteopo-
rosis in man with PCa cannot be neglected.
Wei et al [39] found that 63% of patients who had hor-
mone-naive prostate cancer had osteopenia or osteopo-
rosis. In a larger study, Smith et al [33] demonstrated that
34% prostate cancer patients without exposure to ADT
had dual-energy x-ray absorptiometry (DEXA) criteria
Figure 4 Adjusted risk ratio of fractures for patients under ADT as compared to patients not under ADT.
Table 3: Stratified analyses of pooled relative risk of fractures for patients under androgen deprivation therapy
Stratified Analysis Patients Pooled RR (95% CI) Heterogeneity
Incidence of fractures as the primary outcome
Yes 111,573 1.17 (1.14 - 1.20) 0.0001
No --- --- ---
Type of outcome measure
Self-reported 50,613 1.06 (1.02 - 1.10) Not applicable
Ambulatorial 22,802 1.18 (1.12 - 1.24) 0.02
Bone metastases in the sample
Yes 50,678 1.06 (1.02 - 1.10) 1.18 0.09
No 22,737 (1.12 - 1.23) 0.01
Mean follow-up, y
≥ 5 61,295 1.08 (1.04 - 1.11) 0.04
< 5 12,120 1.29 (1.18 - 1.43) Not applicable
Type of fracture
Lumbar spine fracture 74,394 1.33 (1.22 - 1.45) 0.93
Inferior member fracture 74,394 1.15 (1.10 - 1.20) 0.001Serpa Neto et al. BMC Urology 2010, 10:9
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for osteopenia or osteoporosis. Conde et al [17] reported
a high prevalence of osteopenia (73.5%) and osteoporosis
(17.6%) in 34 men who had non metastatic, hormone-
naive prostate cancer. We could see that prostate cancer
and ADT are strongly associated with bone metabolism
modifications and, in these studies, advanced age, lower
body mass index, and elevated prostate specific antigen
levels correlated significantly with decreased BMD.
Fractures are associated with substantial morbidity and
mortality. Men who experience hip fractures suffer
greater impairment and have a higher rate of fracture-
related mortality than women [46]. Approximately 20% to
30% of hip fractures occur in men, and 50% to 60% of
men die within one year of the fracture [47]. The detri-
mental association between fracture and mortality
extends to men who have prostate cancer. Oefelein and
colleagues identified a negative association between skel-
etal fracture and overall survival in 195 prostate cancer
patients treated with chronic ADT [9].
The bone mass of a normal adult is the outcome of a
dynamic equilibrium between bone formation and bone
resorption. The latter step is regulated by a family of pro-
teins that include receptor activator of nuclear factor k-Β
(RANK), RANK ligand (RANKL) and osteoprotegerin
(OPG). Binding of RANKL to RANK on the surfaces of
osteoclast precursors will trigger maturation, activation,
and prolonged survival of these cells. Thus, RANKL pro-
motes bone resorption. Vitamin D, parathyroid hormone,
tumour necrosis factor-α (TNF-α), activated T-cells, and
glucocorticoid therapy all increase this ratio, promoting
bone resorption. Estrogen deficiency states produce
osteoporosis because normal levels of 17β-estradiol
inhibit RANKL production and stimulate OPG. Testos-
terone stimulates osteoblasts, inhibits the apoptosis of
both osteoblasts and osteoclasts, and is a precursor of
estrogen via aromatization; its net effect is to stimulate
bone formation. In males under ADT, both testosterone
and estrogen levels fall, shifting the balance of bone turn-
over toward resorption [48]. ADT does not have a signifi-
cant impact on serum calcium, 25-hydroxyvitamin D, or
PTH, but epidemiological studies have suggested that
high levels of calcium intake may suppress PTH and ulti-
mately 1,25-dihydroxyvitamin D and associated with
increased risk of prostate cancer [49].
Current American Society of Clinical Oncology
(ASCO) guidelines and expert panels suggest that
patients under ADT with clinically significant bone loss
should receive bisphosphonates, regardless of hormonal
and metastatic status, and preclinical and clinical data
show that bisphosphonates can also prevent and treat
CTILB and may inhibit malignant bone disease develop-
ment in patients with early stage disease [7,10].
Conclusions
We conclude that patients with prostate cancer under
androgen deprivation therapy had lower levels of BMD
and higher rates of osteoporosis and fractures than
patients with PCa not under ADT and healthy controls.
Prostate cancer per se does not seem to be a risk factor for
osteoporosis. However, the incidence of fractures was
higher than that found in healthy controls, indicating that
these patients may have had an additional, albeit
unknown, mechanisms that could explain these findings.
Although several studies in the literature have shown
similar results, our study analyzed a larger number of
studies and patients, providing consistent evidence on
PCa, androgen deprivation therapy, osteoporosis and
fracture risk.
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